CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

HR Notices From October 4

View Comments
(credit: istock) Technology Report
Read More

RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer: RetroSense Therapeutics, an Ann Arbor biotechnology company dedicated to developing gene therapy approaches to vision restoration welcomes Steven Bramer to its senior management team as Chief Development Officer. Bramer has more than 26 years of drug development experience. He has held positions in global companies where he contributed substantially to all stages of development for drugs, biologics, tissues, combination products, and devices. His experience covers a broad range of therapeutic areas, including ophthalmology, and he has dealt extensively with regulatory agencies in the United States and abroad. Bramer has served in leadership roles throughout most of his career, leading departments, teams, and initiatives successfully – including his role as the Chief Drug Development Officer at the Foundation Fighting Blindness. Bramer will play a pivotal role in bringing RetroSense’s lead product, RST-001, into the clinic for the treatment of retinal degenerative conditions, such as retinitis pigmentosa and dry age-related macular degeneration. Bramer holds an AS degree in Biology from Delhi College, BS degree in Animal Science from Cornell University, and has completed a MS rogram in Pathology and a Ph.D. in Pharmaceutics from The Ohio State University. More at www.retro-sense.com

View Comments
blog comments powered by Disqus